Hepatitis Alert: How Recent Drug Approvals Affect First-line HCV Treatment

Join us for the first Webinar in a series providing rapid responses to recent practice-changing events in the care of patients with viral hepatitis!

Choose from one of 3 live, 45-minute, CME/CE/CPE-certified Webinars on this topic, in which Jordan J. Feld, MD, MPH; Nancy Reau, MD, FAASLD, AGAF; or Stefan Zeuzem, MD, will provide expert insight into how recent drug approvals affect the treatment landscape for newly diagnosed patients with HCV.

Agenda

  • Changes in HCV Epidemiology
  • Current Recommendations for First-line Treatment
  • Recent Drug Approvals: Efficacy and Use
  • Question and Answer Session

Events

Date / Time
Event Details

Faculty

Faculty
Jordan J. Feld, MD, MPH

Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Faculty
Nancy Reau, MD, FAASLD, AGAF

Chief, Section of Hepatology
Associate Director,Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois

Faculty
Stefan Zeuzem, MD

Professor of Medicine 
Chief, Department of Medicine I 
JW Goethe University Hospital 
Frankfurt, Germany

CME

Program Overview
A series of live Webinars in which expert faculty review key data and provide perspectives on the impact of new developments in the care of patients with viral hepatitis.

Goal
The goal of this activity is to improve participants’ confidence and competence in incorporating best practices and emerging data into their patient care strategies for patients with viral hepatitis.

Target Audience
This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals involved in the management of patients with viral hepatitis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select appropriate regimens for treatment-naive HCV-infected patients based on study data and approved indications
  • Pharmacists should be able to provide appropriate guidance on evolving best practices in viral hepatitis management to patients and the treatment team
  • Nurses should be able to provide counsel and support to patients and their families

Accreditation

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement 
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
This educational activity for .7 contact hour is provided by Postgraduate Institute for Medicine.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Pharmacist Continuing Education
ACPE logo
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for .75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-17-919-L01-P.

Type of Activity
Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.